Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

1. (Currently Amended) A compound of the formula:



or a pharmaceutically acceptable ~~form thereof~~salt thereof, wherein:

A and B are independently CR_2 or N;

X and Y are independently CR_x or N;

R_x is independently chosen at each occurrence from hydrogen, C_1-C_6alkyl, amino and cyano;

R_1 represents from 0 to 3 substituents independently chosen from halogen, hydroxy, amino, cyano, -COOH, aminocarbonyl, C_1-C_6alkyl, C_1-C_6alkoxy, C_2-C_6alkyl ether, C_2-C_6alkanoyl, C_3-C_6alkanone, C_1-C_6hydroxyalkyl, C_1-C_6haloalkyl, C_1-C_6haloalkoxy, mono- and di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, mono- and di-(C_1-C_6alkyl)sulfonamido, and mono- and di-(C_1-C_6alkyl)aminocarbonyl;

Each R_2 is:

(i) independently chosen from hydrogen, hydroxy, amino, cyano, halogen, C_1-C_6haloalkyl, C_2-C_6alkyl ether, C_2-C_6alkanoyl, C_3-C_6alkanone, mono- and di-(C_1-

C_6alkyl)aminoC_0-C_4alkyl, C_1-C_6alkylsulfonyl, mono- and di-(C_1-C_6alkyl)sulfonamido, and mono- and di-(C_1-C_6alkyl)aminocarbonyl; or

(ii) taken together with an adjacent R_2 to form a fused 5- to 10-membered carbocyclic or heterocyclic group that is substituted with from 0 to 3 substituents independently chosen from halogen, oxo and C_1-C_6alkyl;

R_3 is selected from:

(i) hydrogen, hydroxy, halogen and C_1-C_6haloalkyl;

(ii) C_1-C_6alkyl, (C_3-C_8cycloalkyl)C_0-C_4alkyl, phenylC_0-C_4alkyl and pyridylC_0-C_4alkyl; and

(iii) groups of the formula



wherein

L is a single covalent bond or C_1-C_6alkylene;

R_5 and R_6 are:

(a) independently chosen from hydrogen, C_1-C_8alkyl, (C_3-C_8cycloalkyl)C_0-C_4alkyl, (3- to 7-membered heterocycloalkyl)C_0-C_4alkyl, C_1-C_8alkenyl, C_2-C_8alkanoyl, phenylC_0-C_6alkyl, pyridylC_0-C_6alkyl and groups that are joined to L to form a 5- to 7-membered heterocycloalkyl, such that neither R_5 nor R_6 is phenyl or pyridyl if L is a bond; or

(b) taken together to form a 5- to 7-membered heterocycloalkyl; and

R_7 is C_1-C_8alkyl, (C_3-C_8cycloalkyl)C_0-C_4alkyl, C_1-C_8alkenyl, C_2-C_8alkanoyl, phenylC_0-C_6alkyl, pyridylC_0-C_6alkyl or a group that is joined to L to form a 5- to 7-membered heterocycloalkyl;

wherein each of (ii) and (iii) is substituted with from 0 to 4 substituents independently chosen from halogen, cyano, amino, hydroxy, oxo, C_1-C_6alkyl, C_3-C_8cycloalkyl, C_2-C_6alkyl ether, C_1-C_6alkoxy, C_2-C_6alkanoyl, C_1-C_6haloalkyl, mono- and di-(C_1-C_6alkyl)amino, phenyl, 5- to 6-membered heteroaryl and 4- to 8-membered heterocycloalkyl, wherein each phenyl, heteroaryl and heterocycloalkyl is substituted

with from 0 to 2 secondary substituents independently chosen from halogen, hydroxy, amino, cyano, C_1-C_4alkyl, C_1-C_4alkoxy and C_1-C_4haloalkyl; and

R_4 represents from 0 to 2 substituents independently chosen from oxo, C_1-C_4alkyl, C_1-C_4haloalkyl.

2-4. (Cancelled).

5. (Original) A compound or pharmaceutically acceptable ~~form thereof~~salt thereof according to claim 1, wherein R_3 is a group of the formula:

 wherein:

L is a single covalent bond or C_1-C_4alkylene; and

R_5 and R_6 are:

(a) independently chosen from hydrogen, C_1-C_6alkyl and C_1-C_6alkenyl; or

(b) taken together to form a 5- to 7-membered heterocycloalkyl;

wherein each of which alkyl, alkenyl and heterocycloalkyl is substituted with from 0 to 3 substituents independently chosen from halogen, amino, hydroxy, oxo, C_1-C_4alkyl, C_2-C_4alkyl ether, C_1-C_4alkoxy, C_1-C_4haloalkyl and mono- and di-(C_1-C_4alkyl)amino.

6-7. (Cancelled).

8. (Currently Amended) A compound or pharmaceutically acceptable ~~form thereof~~salt thereof according to claim 1, wherein R_3 is a group of the formula:

 wherein:

L is a single covalent bond or C_1-C_4alkylene; and

R_7 is hydrogen, C_1-C_6alkyl or phenylC_0-C_6alkyl, wherein each alkyl and phenylalkyl is substituted with from 0 to 3 substituents independently chosen from halogen, hydroxy, oxo, cyano, amino, C_1-C_4alkyl, C_1-C_6haloalkyl and C_1-C_6alkoxy.

9-14. (Cancelled).

15. (Currently Amended) A compound or pharmaceutically acceptable ~~form thereof~~salt thereof according to claim 1, wherein the compound has the formula:



wherein:

R_{1a} is halogen, amino, cyano, -COOH, C_1-C_6alkyl, C_1-C_6alkoxy, C_1-C_6haloalkyl, C_1-C_6alkylsulfonyl or mono- or di-(C_1-C_6alkyl)sulfonamido;

R_{1b} is hydrogen, halogen, amino, hydroxy, cyano, -COOH, aminocarbonyl, C_1-C_4alkyl, C_1-C_4alkoxy, C_1-C_6hydroxyalkyl or C_1-C_4haloalkyl; and

R_{4a} is hydrogen or methyl.

16-17. (Cancelled).

18. (Currently Amended) A compound of the formula:



or a pharmaceutically acceptable ~~form thereof~~salt thereof, wherein:

A and B are independently CR_2 or N;

D is CH or N;

X, Y and Z are independently CR_x or N, such that at least one of X, Y and Z is N;

R_x is independently chosen at each occurrence from hydrogen, C_1-C_6alkyl, amino and cyano;

R_1 represents from 0 to 3 substituents independently chosen from halogen, hydroxy, amino, cyano, -COOH, aminocarbonyl, C_1-C_6alkyl, C_1-C_6alkoxy, C_2-C_6alkyl ether, C_2-C_6alkanoyl, C_3-C_6alkanone, C_1-C_6hydroxyalkyl, C_1-C_6haloalkyl, C_1-C_6haloalkoxy, mono- and di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, mono- and di-(C_1-C_6alkyl)sulfonamido, and mono- and di-(C_1-C_6alkyl)aminocarbonyl;

Each R_2 is:

(i) independently chosen from hydrogen, hydroxy, amino, cyano, nitro, halogen, C_1-C_6alkyl, C_3-C_8cycloalkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_2-C_6alkyl ether, C_1-C_6alkoxycarbonyl, C_2-C_6alkanoyl, C_3-C_6alkanone, C_1-C_6hydroxyalkyl, C_1-C_6cyanoalkyl, C_1-C_6aminoalkyl, mono- and di-(C_1-C_6alkyl)aminoC_0-C_4alkyl, C_1-C_6alkylsulfonyl, mono- and di-(C_1-C_6alkyl)sulfonamido, mono- and di-(C_1-C_6alkyl)aminocarbonyl and (4- to 8-membered heterocycloalkyl)C_0-C_4alkyl; or

(ii) taken together with an adjacent R_2 to form a fused 5- to 10-membered carbocyclic or heterocyclic group that is substituted with from 0 to 3 substituents independently chosen from halogen, oxo and C_1-C_6alkyl;

R_3 is selected from:

(i) hydrogen, hydroxy, halogen, cyano and C_1-C_6haloalkyl;

(ii) C_1-C_6alkyl, (C_3-C_8cycloalkyl)C_0-C_4alkyl, phenylC_0-C_4alkyl and pyridylC_0-C_4alkyl; and

(iii) groups of the formula:



or


wherein

L is a single covalent bond or C_1-C_6alkylene;

R_5 and R_6 are:

(a) independently chosen from hydrogen, C_1-C_8alkyl, C_1-C_8alkenyl, C_2-C_8alkanoyl, (C_3-C_8cycloalkyl)C_0-C_4alkyl, (3- to 7-membered heterocycloalkyl)C_0-C_4alkyl, phenylC_0-C_6alkyl, pyridylC_0-C_6alkyl and groups that are joined to L to form a 5- to 7-membered heterocycloalkyl; or

(b) taken together to form a 5- to 7-membered heterocycloalkyl; and

R_7 is C_1-C_8alkyl, (C_3-C_8cycloalkyl)C_0-C_4alkyl, C_1-C_8alkenyl, C_2-C_8alkanoyl, phenylC_0-C_6alkyl, pyridylC_0-C_6alkyl or a group that is joined to L to form a 5- to 7-membered heterocycloalkyl;

wherein each of (ii) and (iii) is substituted on from 0 to 3 carbon atoms with substituents independently chosen from halogen, cyano, amino, hydroxy, oxo, C_1-C_6alkyl, C_3-C_8cycloalkyl, C_2-C_6alkyl ether, C_1-C_6alkoxy, C_2-C_6alkanoyl, C_1-C_6haloalkyl, mono- and di-(C_1-C_6alkyl)amino, phenyl, 5- to 6-membered heteroaryl and 4- to 8-membered heterocycloalkyl, wherein each phenyl, heteroaryl and heterocycloalkyl is substituted with from 0 to 2 secondary substituents independently chosen from halogen, hydroxy, amino, cyano, C_1-C_4alkyl, C_1-C_4alkoxy and C_1-C_4haloalkyl; and

R_{4a} is methyl or C_1haloalkyl.

19-27. (Cancelled).

28. (Currently Amended) A compound or pharmaceutically acceptable ~~form thereof~~salt thereof according to claim 18, wherein each R_2 is independently chosen from hydrogen, amino, cyano, halogen, C_1-C_6alkyl, C_3-C_8cycloalkyl, C_1-C_6haloalkyl, C_2-C_6alkyl ether, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6hydroxyalkyl, C_1-C_6cyanoalkyl, C_1-C_6alkylsulfonyl and mono- and di-(C_1-C_6alkyl)sulfonamido.

29-34. (Cancelled).

35. (Currently Amended) A compound or pharmaceutically acceptable ~~form thereof~~salt thereof according to claim 18, wherein the compound has the formula:



wherein R_{1a} is halogen, amino, cyano, -COOH, C_1-C_6alkyl, C_1-C_6alkoxy, C_1-C_6haloalkyl, C_1-C_6alkylsulfonyl or mono- or di-(C_1-C_6alkyl)sulfonamido; and

R_{1b} is hydrogen, halogen, amino, hydroxy, cyano, -COOH, aminocarbonyl, C_1-C_4alkyl, C_1-C_4alkoxy, C_1-C_6hydroxyalkyl or C_1-C_4haloalkyl.

36-37. (Cancelled).

38. (Currently Amended) A compound of the formula:



or a pharmaceutically acceptable ~~form thereof~~salt thereof, wherein:

Ar_1 and Ar_2 are independently chosen from phenyl, naphthyl and 5- to 10-membered aromatic heterocycles, each of which is substituted with from 0 to 4 substituents independently chosen from halogen, cyano, amino, hydroxy, nitro, -COOH, aminocarbonyl, C_1-C_6alkyl, C_3-C_8cycloalkyl, C_2-C_6alkyl ether, C_1-C_6alkoxy, C_1-C_6alkoxycarbonyl, C_1-C_6haloalkoxy, C_2-C_6alkanoyl, C_3-C_6alkanone, C_1-C_6hydroxyalkyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6cyanoalkyl, C_1-C_6aminoalkyl, C_1-C_6alkylsulfonyl, mono- and di-(C_1-C_6alkyl)sulfonamido, mono-

and di-(C_1-C_6alkyl)aminocarbonyl, mono- and di-(C_1-C_6alkyl)aminoC_0-C_4alkyl and (4- to 8-membered heterocycloalkyl)C_0-C_4alkyl;

X, Y and Z are independently CR_x or N, such that at least one of X, Y and Z is N;

R_x is independently chosen at each occurrence from hydrogen, C_1-C_6alkyl, amino and cyano;

R_{3a} is selected from:

(i) hydroxy, halogen and C_1-C_6haloalkyl;

(ii) C_1-C_6alkyl, (C_3-C_8cycloalkyl)C_0-C_4alkyl, phenylC_0-C_4alkyl and pyridylC_0-C_4alkyl; and

(iii) groups of the formula



wherein

L is a single covalent bond or C_1-C_6alkyl;

M is C_1-C_6alkyl;

R_5 and R_6 are:

(a) independently chosen from hydrogen, C_1-C_8alkyl, C_1-C_8alkenyl, C_2-C_8alkanoyl, (C_3-C_8cycloalkyl)C_0-C_4alkyl, (3- to 7-membered heterocycloalkyl)C_0-C_4alkyl, phenylC_0-C_6alkyl, pyridylC_0-C_6alkyl and groups that are joined to M to form a 5- to 7-membered heterocycloalkyl; or

(b) taken together to form a 5- to 7-membered heterocycloalkyl; and

R_7 is C_1-C_8alkyl, (C_3-C_8cycloalkyl)C_0-C_4alkyl, C_1-C_8alkenyl, C_2-C_8alkanoyl, phenylC_0-C_6alkyl, pyridylC_0-C_6alkyl or a group that is joined to L to form a 5- to 7-membered heterocycloalkyl;

wherein each of (ii) and (iii) is substituted with from 0 to 4 substituents independently chosen from halogen, cyano, amino, hydroxy, C_1-C_6alkyl, C_3-C_8cycloalkyl, C_2-C_6alkyl ether, C_1-C_6alkoxy, C_2-C_6alkanoyl, C_1-C_6haloalkyl, mono- and di-(C_1-C_6alkyl)amino, phenyl, 5- to 6-membered heteroaryl and 4- to 8-membered heterocycloalkyl, wherein each phenyl, heteroaryl and heterocycloalkyl is substituted

with from 0 to 2 secondary substituents independently chosen from halogen, hydroxy, amino, cyano, C_1-C_4alkyl, C_1-C_4alkoxy and C_1-C_4haloalkyl; and

R_4 represents from 0 to 2 C_{1-6}alkyl substituents.

39-44. (Cancelled).

45. (Currently Amended) A compound or pharmaceutically acceptable ~~form thereof~~salt thereof according to claim 38, having the formula:



wherein:

A and B are independently CR_2 or N;

D is CH or N;

R_1 represents from 0 to 3 substituents independently chosen from halogen, hydroxy, amino, cyano, -COOH, aminocarbonyl, C_1-C_6alkyl, C_1-C_6alkoxy, C_2-C_6alkyl ether, C_2-C_6alkanoyl, C_3-C_6alkanone, C_1-C_6hydroxyalkyl, C_1-C_6haloalkyl, C_1-C_6haloalkoxy, mono- and di-(C_1-C_6alkyl)amino, C_1-C_6alkylsulfonyl, mono- and di-(C_1-C_6alkyl)sulfonamido, and mono- and di-(C_1-C_6alkyl)aminocarbonyl;

Each R_2 is independently hydrogen, halogen, cyano, amino, hydroxy, nitro, C_1-C_6alkyl, C_3-C_8cycloalkyl, C_2-C_6alkyl ether, C_1-C_6alkoxy, C_1-C_6alkoxycarbonyl, C_1-C_6haloalkoxy, C_2-C_6alkanoyl, C_3-C_6alkanone, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6cyanoalkyl, C_1-C_6aminoalkyl, C_1-C_6alkylsulfonyl, mono- or di-(C_1-C_6alkyl)sulfonamido, mono- or di-(C_1-C_6alkyl)aminocarbonyl, mono- or di-(C_1-C_6alkyl)aminoC_0-C_4alkyl or (4- to 8-membered heterocycloalkyl)C_0-C_4alkyl; and

R_{4a} is hydrogen, oxo, methyl or C_1haloalkyl.

46-60. (Cancelled).

61. (Currently Amended) A pharmaceutical composition, comprising at least one compound or pharmaceutically acceptable ~~form thereof~~salt thereof according to ~~any one of claims 1, 18 or 38~~claim 1 in combination with a physiologically acceptable carrier or excipient.

62. (Original) A pharmaceutical composition according to claim 61 wherein the composition is formulated as an injectible fluid, an aerosol, a cream, a gel, a pill, a capsule, a syrup or a transdermal patch.

63. (Currently Amended) A method for reducing calcium conductance of a cellular capsaicin receptor, comprising contacting a cell expressing a capsaicin receptor with at least one compound having the formula:



or a pharmaceutically acceptable ~~form thereof~~salt thereof, wherein

Ar_1 and Ar_2 are independently chosen from phenyl, naphthyl and 5- to 10-membered aromatic heterocycles, each of which is substituted with from 0 to 4 substituents independently chosen from halogen, cyano, amino, hydroxy, nitro, -COOH, aminocarbonyl, C_1-C_6alkyl, C_3-C_8cycloalkyl, C_2-C_6alkyl ether, C_1-C_6alkoxy, C_1-C_6alkoxycarbonyl, C_1-C_6haloalkoxy, C_2-C_6alkanoyl, C_3-C_6alkanone, C_1-C_6hydroxyalkyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6cyanoalkyl, C_1-C_6aminoalkyl, C_1-C_6alkylsulfonyl, mono- and di-(C_1-C_6alkyl)sulfonamido, mono- and di-(C_1-C_6alkyl)aminocarbonyl, mono- and di-(C_1-C_6alkyl)aminoC_0-C_4alkyl and (4- to 8-membered heterocycloalkyl)C_0-C_4alkyl;

X, Y and Z are independently CR_x or N, such that at least one of X, Y and Z is N;

R_x is independently chosen at each occurrence from hydrogen, C_1-C_6alkyl, amino and cyano;

R_3 is selected from:

(i) hydrogen, hydroxy, halogen and C_1-C_6haloalkyl;

(ii) C_1-C_6alkyl, (C_3-C_8cycloalkyl)C_0-C_4alkyl, phenylC_0-C_4alkyl and pyridylC_0-C_4alkyl; and

(iii) groups of the formula



wherein

L is a single covalent bond or C_1-C_6alkylene;

R_5 and R_6 are:

(a) independently chosen from hydrogen, C_1-C_8alkyl, C_1-C_8alkenyl, C_2-C_8alkanoyl, (C_3-C_8cycloalkyl)C_0-C_4alkyl, (3- to 7-membered heterocycloalkyl)C_0-C_4alkyl, phenylC_0-C_6alkyl, pyridylC_0-C_6alkyl and groups that are joined to L to form a 5- to 7-membered heterocycloalkyl; or

(b) taken together to form a 5- to 7-membered heterocycloalkyl; and

R_7 is C_1-C_8alkyl, (C_3-C_8cycloalkyl)C_0-C_4alkyl, C_1-C_8alkenyl, C_2-C_8alkanoyl, phenylC_0-C_6alkyl, pyridylC_0-C_6alkyl or a group that is joined to L to form a 5- to 7-membered heterocycloalkyl;

wherein each of (ii) and (iii) is substituted with from 0 to 4 substituents independently chosen from halogen, cyano, amino, hydroxy, oxo, C_1-C_6alkyl, C_3-C_8cycloalkyl, C_2-C_6alkyl ether, C_1-C_6alkoxy, C_2-C_6alkanoyl, C_1-C_6haloalkyl, mono- and di-(C_1-C_6alkyl)amino, phenyl, 5- to 6-membered heteroaryl and 4- to 8-membered heterocycloalkyl, wherein each phenyl, heteroaryl and heterocycloalkyl is substituted with from 0 to 2 secondary substituents independently chosen from halogen, hydroxy, amino, cyano, C_1-C_4alkyl, C_1-C_4alkoxy and C_1-C_4haloalkyl; and

R_4 represents from 0 to 2 substituents independently chosen from oxo, C_1-C_4alkyl, C_1-C_4haloalkyl;

and thereby reducing calcium conductance of the capsaicin receptor.

64-75. (Cancelled).

76. (Currently Amended) A method for inhibiting binding of vanilloid ligand to a capsaicin receptor *in vitro*, the method comprising contacting capsaicin receptor with at least one compound having the formula:



or a pharmaceutically acceptable ~~form thereof~~salt thereof, wherein

Ar_1 and Ar_2 are independently chosen from phenyl, naphthyl and 5- to 10-membered aromatic heterocycles, each of which is substituted with from 0 to 4 substituents independently chosen from halogen, cyano, amino, hydroxy, nitro, -COOH, aminocarbonyl, C_1-C_6alkyl, C_3-C_8cycloalkyl, C_2-C_6alkyl ether, C_1-C_6alkoxy, C_1-C_6alkoxycarbonyl, C_1-C_6haloalkoxy, C_2-C_6alkanoyl, C_3-C_6alkanone, C_1-C_6hydroxyalkyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6cyanoalkyl, C_1-C_6aminoalkyl, C_1-C_6alkylsulfonyl, mono- and di-(C_1-C_6alkyl)sulfonamido, mono- and di-(C_1-C_6alkyl)aminocarbonyl, mono- and di-(C_1-C_6alkyl)aminoC_0-C_4alkyl and (4- to 8-membered heterocycloalkyl)C_0-C_4alkyl;

X, Y and Z are independently CR_x or N, such that at least one of X, Y and Z is N;

R_x is independently chosen at each occurrence from hydrogen, C_1-C_6alkyl, amino and cyano;

R_3 is selected from:

(i) hydrogen, hydroxy, halogen and C_1-C_6haloalkyl;

(ii) C_1-C_6alkyl, (C_3-C_8cycloalkyl)C_0-C_4alkyl, phenylC_0-C_4alkyl and pyridylC_0-C_4alkyl; and

(iii) groups of the formula



wherein

L is a single covalent bond or C_1-C_6alkylene;

R_5 and R_6 are:

(a) independently chosen from hydrogen, C_1-C_8alkyl, C_1-C_8alkenyl, C_2-C_8alkanoyl, (C_3-C_8cycloalkyl)C_0-C_4alkyl, (3- to 7-membered heterocycloalkyl)C_0-C_4alkyl, phenylC_0-C_6alkyl, pyridylC_0-C_6alkyl and groups that are joined to L to form a 5- to 7-membered heterocycloalkyl; or

(b) taken together to form a 5- to 7-membered heterocycloalkyl; and

R_7 is C_1-C_8alkyl, (C_3-C_8cycloalkyl)C_0-C_4alkyl, C_1-C_8alkenyl, C_2-C_8alkanoyl, phenylC_0-C_6alkyl, pyridylC_0-C_6alkyl or a group that is joined to L to form a 5- to 7-membered heterocycloalkyl;

wherein each of (ii) and (iii) is substituted with from 0 to 4 substituents independently chosen from halogen, cyano, amino, hydroxy, oxo, C_1-C_6alkyl, C_3-C_8cycloalkyl, C_2-C_6alkyl ether, C_1-C_6alkoxy, C_2-C_6alkanoyl, C_1-C_6haloalkyl, mono- and di-(C_1-C_6alkyl)amino, phenyl, 5- to 6-membered heteroaryl and 4- to 8-membered heterocycloalkyl, wherein each phenyl, heteroaryl and heterocycloalkyl is substituted with from 0 to 2 secondary substituents independently chosen from halogen, hydroxy, amino, cyano, C_1-C_4alkyl, C_1-C_4alkoxy and C_1-C_4haloalkyl; and

R_4 represents from 0 to 2 substituents independently chosen from oxo, C_1-C_4alkyl, C_1-C_4haloalkyl;

under conditions and in an amount sufficient to detectably inhibit vanilloid ligand binding to capsaicin receptor.

77-79. (Cancelled).

80. (Currently Amended) A method for inhibiting binding of vanilloid ligand to a capsaicin receptor in a patient, the method comprising contacting cells expressing capsaicin receptor with at least one compound having the formula:



or a pharmaceutically acceptable ~~form thereof~~salt thereof, wherein

Ar_1 and Ar_2 are independently chosen from phenyl, naphthyl and 5- to 10-membered aromatic heterocycles, each of which is substituted with from 0 to 4 substituents independently chosen from halogen, cyano, amino, hydroxy, nitro, -COOH, aminocarbonyl, C_1-C_6alkyl, C_3-C_8cycloalkyl, C_2-C_6alkyl ether, C_1-C_6alkoxy, C_1-C_6alkoxycarbonyl, C_1-C_6haloalkoxy, C_2-C_6alkanoyl, C_3-C_6alkanone, C_1-C_6hydroxyalkyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6cyanoalkyl, C_1-C_6aminoalkyl, C_1-C_6alkylsulfonyl, mono- and di-(C_1-C_6alkyl)sulfonamido, mono- and di-(C_1-C_6alkyl)aminocarbonyl, mono- and di-(C_1-C_6alkyl)aminoC_0-C_4alkyl and (4- to 8-membered heterocycloalkyl)C_0-C_4alkyl;

X, Y and Z are independently CR_x or N, such that at least one of X, Y and Z is N;

R_x is independently chosen at each occurrence from hydrogen, C_1-C_6alkyl, amino and cyano;

R_3 is selected from:

(i) hydrogen, hydroxy, halogen and C_1-C_6haloalkyl;

(ii) C_1-C_6alkyl, (C_3-C_8cycloalkyl)C_0-C_4alkyl, phenylC_0-C_4alkyl and pyridylC_0-C_4alkyl; and

(iii) groups of the formula



wherein

L is a single covalent bond or C_1-C_6alkylene;

R_5 and R_6 are:

(a) independently chosen from hydrogen, C_1-C_8alkyl, C_1-C_8alkenyl, C_2-C_8alkanoyl, (C_3-C_8cycloalkyl)C_0-C_4alkyl, (3- to 7-membered heterocycloalkyl)C_0-C_4alkyl, phenylC_0-C_6alkyl, pyridylC_0-C_6alkyl and groups that are joined to L to form a 5- to 7-membered heterocycloalkyl; or

(b) taken together to form a 5- to 7-membered heterocycloalkyl; and

R_7 is C_1-C_8alkyl, (C_3-C_8cycloalkyl)C_0-C_4alkyl, C_1-C_8alkenyl, C_2-C_8alkanoyl, phenylC_0-C_6alkyl, pyridylC_0-C_6alkyl or a group that is joined to L to form a 5- to 7-membered heterocycloalkyl;

wherein each of (ii) and (iii) is substituted with from 0 to 4 substituents independently chosen from halogen, cyano, amino, hydroxy, oxo, C_1-C_6alkyl, C_3-C_8cycloalkyl, C_2-C_6alkyl ether, C_1-C_6alkoxy, C_2-C_6alkanoyl, C_1-C_6haloalkyl, mono- and di-(C_1-C_6alkyl)amino, phenyl, 5- to 6-membered heteroaryl and 4- to 8-membered heterocycloalkyl, wherein each phenyl, heteroaryl and heterocycloalkyl is substituted with from 0 to 2 secondary substituents independently chosen from halogen, hydroxy, amino, cyano, C_1-C_4alkyl, C_1-C_4alkoxy and C_1-C_4haloalkyl; and

R_4 represents from 0 to 2 substituents independently chosen from oxo, C_1-C_4alkyl, C_1-C_4haloalkyl;

in an amount sufficient to detectably inhibit vanilloid ligand binding to cells expressing a cloned capsaicin receptor *in vitro*, and thereby inhibiting binding of vanilloid ligand to the capsaicin receptor in the patient.

81-83. (Cancelled).

84. (Currently Amended) A method for treating a condition responsive to capsaicin receptor modulation in a patient, comprising administering to the patient a capsaicin receptor modulatory amount of a compound having the formula:



or a pharmaceutically acceptable ~~form thereof~~salt thereof, wherein

Ar_1 and Ar_2 are independently chosen from phenyl, naphthyl and 5- to 10-membered aromatic heterocycles, each of which is substituted with from 0 to 4 substituents independently chosen from halogen, cyano, amino, hydroxy, nitro, -COOH, aminocarbonyl, C_1-C_6alkyl, C_3-C_8cycloalkyl, C_2-C_6alkyl ether, C_1-C_6alkoxy, C_1-C_6alkoxycarbonyl, C_1-C_6haloalkoxy, C_2-C_6alkanoyl, C_3-C_6alkanone, C_1-C_6hydroxyalkyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6cyanoalkyl, C_1-C_6aminoalkyl, C_1-C_6alkylsulfonyl, mono- and di-(C_1-C_6alkyl)sulfonamido, mono- and di-(C_1-C_6alkyl)aminocarbonyl, mono- and di-(C_1-C_6alkyl)aminoC_0-C_4alkyl and (4- to 8-membered heterocycloalkyl)C_0-C_4alkyl;

X, Y and Z are independently CR_x or N, such that at least one of X, Y and Z is N;

R_x is independently chosen at each occurrence from hydrogen, C_1-C_6alkyl, amino and cyano;

R_3 is selected from:

(i) hydrogen, hydroxy, halogen and C_1-C_6haloalkyl;

(ii) C_1-C_6alkyl, (C_3-C_8cycloalkyl)C_0-C_4alkyl, phenylC_0-C_4alkyl and pyridylC_0-C_4alkyl; and

(iii) groups of the formula



wherein

L is a single covalent bond or C_1-C_6alkylene;

R_5 and R_6 are:

(a) independently chosen from hydrogen, C_1-C_8alkyl, C_1-C_8alkenyl, C_2-C_8alkanoyl, (C_3-C_8cycloalkyl)C_0-C_4alkyl, (3- to 7-membered

heterocycloalkyl)C_0-C_4alkyl, phenylC_0-C_6alkyl, pyridylC_0-C_6alkyl and groups that are joined to L to form a 5- to 7-membered heterocycloalkyl; or

(b) taken together to form a 5- to 7-membered heterocycloalkyl; and

R_7 is C_1-C_8alkyl, (C_3-C_8cycloalkyl)C_0-C_4alkyl, C_1-C_8alkenyl, C_2-C_8alkanoyl, phenylC_0-C_6alkyl, pyridylC_0-C_6alkyl or a group that is joined to L to form a 5- to 7-membered heterocycloalkyl;

wherein each of (ii) and (iii) is substituted with from 0 to 4 substituents independently chosen from halogen, cyano, amino, hydroxy, oxo, C_1-C_6alkyl, C_3-C_8cycloalkyl, C_2-C_6alkyl ether, C_1-C_6alkoxy, C_2-C_6alkanoyl, C_1-C_6haloalkyl, mono- and di-(C_1-C_6alkyl)amino, phenyl, 5- to 6-membered heteroaryl and 4- to 8-membered heterocycloalkyl, wherein each phenyl, heteroaryl and heterocycloalkyl is substituted with from 0 to 2 secondary substituents independently chosen from halogen, hydroxy, amino, cyano, C_1-C_4alkyl, C_1-C_4alkoxy and C_1-C_4haloalkyl; and

R_4 represents from 0 to 2 substituents independently chosen from oxo, C_1-C_4alkyl, C_1-C_4haloalkyl;

and thereby alleviating the condition in the patient.

85. (Original) A method according to claim 84, wherein the patient is suffering from (i) exposure to capsaicin, (ii) burn or irritation due to exposure to heat, (iii) burns or irritation due to exposure to light, (iv) burn, bronchoconstriction or irritation due to exposure to tear gas, air pollutants or pepper spray, or (v) burn or irritation due to exposure to acid.

86. (Original) A method according to claim 84, wherein the condition is asthma or chronic obstructive pulmonary disease.

87-89. (Cancelled).

90. (Currently Amended) A method for treating pain in a patient, comprising administering to a patient suffering from pain a capsaicin receptor modulatory amount of at least one compound having the formula:



or a pharmaceutically acceptable ~~form thereof~~salt thereof, wherein

Ar_1 and Ar_2 are independently chosen from phenyl, naphthyl and 5- to 10-membered aromatic heterocycles, each of which is substituted with from 0 to 4 substituents independently chosen from halogen, cyano, amino, hydroxy, nitro, -COOH, aminocarbonyl C_1-C_6alkyl, C_3-C_8cycloalkyl, C_2-C_6alkyl ether, C_1-C_6alkoxy, C_1-C_6alkoxycarbonyl, C_1-C_6haloalkoxy, C_2-C_6alkanoyl, C_3-C_6alkanone, C_1-C_6hydroxyalkyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6cyanoalkyl, C_1-C_6aminoalkyl, C_1-C_6alkylsulfonyl, mono- and di-(C_1-C_6alkyl)sulfonamido, mono- and di-(C_1-C_6alkyl)aminocarbonyl, mono- and di-(C_1-C_6alkyl)aminoC_0-C_4alkyl and (4- to 8-membered heterocycloalkyl)C_0-C_4alkyl;

X, Y and Z are independently CR_x or N, such that at least one of X, Y and Z is N;

R_x is independently chosen at each occurrence from hydrogen, C_1-C_6alkyl, amino and cyano;

R_3 is selected from:

(i) hydrogen, hydroxy, halogen and C_1-C_6haloalkyl;

(ii) C_1-C_6alkyl, (C_3-C_8cycloalkyl)C_0-C_4alkyl, phenylC_0-C_4alkyl and pyridylC_0-C_4alkyl; and

(iii) groups of the formula



wherein

L is a single covalent bond or C_1-C_6alkylene;

R_5 and R_6 are:

(a) independently chosen from hydrogen, C_1-C_8alkyl, C_1-C_8alkenyl, C_2-C_8alkanoyl, (C_3-C_8cycloalkyl)C_0-C_4alkyl, (3- to 7-membered

heterocycloalkyl)C_0-C_4alkyl, phenylC_0-C_6alkyl, pyridylC_0-C_6alkyl and groups that are joined to L to form a 5- to 7-membered heterocycloalkyl; or

(b) taken together to form a 5- to 7-membered heterocycloalkyl; and

R_7 is C_1-C_8alkyl, (C_3-C_8cycloalkyl)C_0-C_4alkyl, C_1-C_8alkenyl, C_2-C_8alkanoyl, phenylC_0-C_6alkyl, pyridylC_0-C_6alkyl or a group that is joined to L to form a 5- to 7-membered heterocycloalkyl;

wherein each of (ii) and (iii) is substituted with from 0 to 4 substituents independently chosen from halogen, cyano, amino, hydroxy, oxo, C_1-C_6alkyl, C_3-C_8cycloalkyl, C_2-C_6alkyl ether, C_1-C_6alkoxy, C_2-C_6alkanoyl, C_1-C_6haloalkyl, mono- and di-(C_1-C_6alkyl)amino, phenyl, 5- to 6-membered heteroaryl and 4- to 8-membered heterocycloalkyl, wherein each phenyl, heteroaryl and heterocycloalkyl is substituted with from 0 to 2 secondary substituents independently chosen from halogen, hydroxy, amino, cyano, C_1-C_4alkyl, C_1-C_4alkoxy and C_1-C_4haloalkyl; and

R_4 represents from 0 to 2 substituents independently chosen from oxo, C_1-C_4alkyl, C_1-C_4haloalkyl;

and thereby alleviating pain in the patient.

91. (Cancelled).

92. (Original) A method according to claim 90, wherein the patient is suffering from neuropathic pain.

93. (Original) A method according to claim 90, wherein the pain is associated with a condition selected from: postmastectomy pain syndrome, stump pain, phantom limb pain, oral neuropathic pain, toothache, postherpetic neuralgia, diabetic neuropathy, reflex sympathetic dystrophy, trigeminal neuralgia, osteoarthritis, rheumatoid arthritis, fibromyalgia, Guillain-Barre syndrome, meralgia paresthetica, burning-mouth syndrome, bilateral peripheral neuropathy, causalgia, neuritis, neuronitis, neuralgia, AIDS-related neuropathy, MS-related neuropathy, spinal cord injury-related pain, surgery-related pain, musculoskeletal pain, back pain, headache, migraine, angina,

labor, hemorrhoids, dyspepsia, Charcot's pains, intestinal gas, menstruation, cancer, venom exposure, irritable bowel syndrome, inflammatory bowel disease, and/or trauma.

94. (Cancelled).

95. (Original) A method according to claim 90, wherein the compound is a compound according to claim 1.

96. (Original) A method according to claim 90, wherein the compound is a compound according to claim 18.

97. (Original) A method according to claim 90, wherein the compound is a compound according to claim 38.

98. (Cancelled).

99. (Currently Amended) A method for treating urinary incontinence or overactive bladder in a patient, comprising administering to a patient a capsaicin receptor modulatory amount of a compound having the formula:



or a pharmaceutically acceptable ~~form thereof~~salt thereof, wherein

Ar_1 and Ar_2 are independently chosen from phenyl, naphthyl and 5- to 10-membered aromatic heterocycles, each of which is substituted with from 0 to 4 substituents independently chosen from halogen, cyano, amino, hydroxy, nitro, -COOH, aminocarbonyl, C_1-C_6alkyl, C_3-C_8cycloalkyl, C_2-C_6alkyl ether, C_1-C_6alkoxy, C_1-C_6alkoxycarbonyl, C_1-C_6haloalkoxy, C_2-C_6alkanoyl, C_3-C_6alkanone, C_1-C_6hydroxyalkyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6cyanoalkyl, C_1-C_6aminoalkyl, C_1-C_6alkylsulfonyl, mono- and di-(C_1-C_6alkyl)sulfonamido, mono-

and di-(C_1-C_6alkyl)aminocarbonyl, mono- and di-(C_1-C_6alkyl)aminoC_0-C_4alkyl and (4- to 8-membered heterocycloalkyl)C_0-C_4alkyl;

X, Y and Z are independently CR_x or N, such that at least one of X, Y and Z is N;

R_x is independently chosen at each occurrence from hydrogen, C_1-C_6alkyl, amino and cyano;

R_3 is selected from:

(i) hydrogen, hydroxy, halogen and C_1-C_6haloalkyl;

(ii) C_1-C_6alkyl, (C_3-C_8cycloalkyl)C_0-C_4alkyl, phenylC_0-C_4alkyl and pyridylC_0-C_4alkyl; and

(iii) groups of the formula



wherein

L is a single covalent bond or C_1-C_6alkylene;

R_5 and R_6 are:

(a) independently chosen from hydrogen, C_1-C_8alkyl, C_1-C_8alkenyl, C_2-C_8alkanoyl, (C_3-C_8cycloalkyl)C_0-C_4alkyl, (3- to 7-membered heterocycloalkyl)C_0-C_4alkyl, phenylC_0-C_6alkyl, pyridylC_0-C_6alkyl and groups that are joined to L to form a 5- to 7-membered heterocycloalkyl; or

(b) taken together to form a 5- to 7-membered heterocycloalkyl; and

R_7 is C_1-C_8alkyl, (C_3-C_8cycloalkyl)C_0-C_4alkyl, C_1-C_8alkenyl, C_2-C_8alkanoyl, phenylC_0-C_6alkyl, pyridylC_0-C_6alkyl or a group that is joined to L to form a 5- to 7-membered heterocycloalkyl;

wherein each of (ii) and (iii) is substituted with from 0 to 4 substituents independently chosen from halogen, cyano, amino, hydroxy, oxo, C_1-C_6alkyl, C_3-C_8cycloalkyl, C_2-C_6alkyl ether, C_1-C_6alkoxy, C_2-C_6alkanoyl, C_1-C_6haloalkyl, mono- and di-(C_1-C_6alkyl)amino, phenyl, 5- to 6-membered heteroaryl and 4- to 8-membered heterocycloalkyl, wherein each phenyl, heteroaryl and heterocycloalkyl is substituted

with from 0 to 2 secondary substituents independently chosen from halogen, hydroxy, amino, cyano, C_1-C_4alkyl, C_1-C_4alkoxy and C_1-C_4haloalkyl; and

R_4 represents from 0 to 2 substituents independently chosen from oxo, C_1-C_4alkyl, C_1-C_4haloalkyl;

and thereby alleviating urinary incontinence or overactive bladder in the patient.

100-106. (Cancelled).

107. (Currently Amended) A packaged pharmaceutical preparation, comprising:

(a) a pharmaceutical composition according to claim ~~59~~ 61 in a container; and

(b) instructions for using the composition to treat pain.

108. (Cancelled).

109. (Currently Amended) A packaged pharmaceutical preparation, comprising:

(a) a pharmaceutical composition according to claim ~~59~~ 61 in a container; and

(b) instructions for using the composition to treat urinary incontinence or overactive bladder.

110-111. (Cancelled).

112. (Currently Amended) A compound or pharmaceutically acceptable salt thereof selected from the group consisting of (3,4-Difluoro-phenyl)-{2-(2,6-dimethyl-morpholin-4-ylmethyl)-6-[4-(3-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-pyrimidin-4-yl}-amine ~~or a pharmaceutically acceptable form thereof.~~;

(3,4-Difluoro-phenyl)-{2-methoxymethyl-6-[4-(3-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-pyrimidin-4-yl}-amine;

(3,4-Difluorophenyl)-(5-methyl-2-morpholin-4-yl-6-{4-[3-(trifluoromethyl)(2-pyridyl)]piperazinyl}pyrimidin-4-yl)amine;

(3,4-Difluoro-phenyl)-{2-morpholin-4-ylmethyl-6-[4-(3-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-pyrimidin-4-yl}-amine;

(3,4-Difluoro-phenyl)-{4-[4-(3-methanesulfonyl-pyridin-2-yl)-2-methyl-piperazin-1-yl]-6-morpholin-4-yl-[1,3,5]triazin-2-yl}-amine (R);

(3,4-Difluoro-phenyl)-{4-morpholin-4-yl-6-[4-(3-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-[1,3,5]triazin-2-yl}-amine;

(3-Chloro-phenyl)-{4-[4-(3-chloro-pyridin-2-yl)-piperazin-1-yl]-6-morpholin-4-yl-[1,3,5]triazin-2-yl}-amine;

(3-Chloro-phenyl)-{4-morpholin-4-yl-6-[4-(3-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-[1,3,5]triazin-2-yl}-amine;

(3-Chloro-phenyl)-{4-morpholin-4-yl-6-[4-(3-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-pyrimidin-2-yl}-amine;

(3-Fluoro-phenyl)-{4-morpholin-4-yl-6-[4-(3-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-[1,3,5]triazin-2-yl}-amine;

(3-Methoxy-phenyl)-{4-morpholin-4-yl-6-[4-(3-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-pyrimidin-2-yl}-amine;

(4-Chloro-phenyl)-{4-[4-(3-chloro-pyridin-2-yl)-piperazin-1-yl]-6-morpholin-4-yl-[1,3,5]triazin-2-yl}-amine;

(4-Chloro-phenyl)-{4-morpholin-4-yl-6-[4-(3-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-[1,3,5]triazin-2-yl}-amine;

(4-Fluoro-phenyl)-[2-morpholin-4-yl-6-(4-pyridin-2-yl-piperazin-1-yl)-pyrimidin-4-yl]-amine;

(4-Fluoro-phenyl)-{4-morpholin-4-yl-6-[4-(3-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-[1,3,5]triazin-2-yl}-amine;

(4-Fluoro-phenyl)-{4-morpholin-4-yl-6-[4-(3-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-pyrimidin-2-yl}-amine;

(4-Fluoro-phenyl)-{6-morpholin-4-yl-2-[4-(3-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-pyrimidin-4-yl}-amine;

(4-Methoxy-phenyl)-{4-morpholin-4-yl-6-[4-(3-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-pyrimidin-2-yl}-amine;

(4-*tert*-Butyl-phenyl)-[4-(4-pyridin-2-yl-piperazin-1-yl)-6-(2-trifluoromethyl-benzyloxy)-[1,3,5]triazin-2-yl]-amine;

(4-*tert*-Butyl-phenyl)-[4-[2-methyl-4-(3-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-6-(2-trifluoromethyl-benzyloxy)-[1,3,5]triazin-2-yl]-amine (R);

(4-*tert*-Butyl-phenyl)-[4-[4-(2-methoxy-phenyl)-piperazin-1-yl]-6-(2-trifluoromethyl-benzyloxy)-[1,3,5]triazin-2-yl]-amine;

(4-*tert*-Butyl-phenyl)-[4-[4-(3-chloro-pyridin-2-yl)-2-methyl-piperazin-1-yl]-6-(2-trifluoromethyl-benzyloxy)-[1,3,5]triazin-2-yl]-amine (R);

(4-*tert*-Butyl-phenyl)-[4-[4-(3-fluoro-pyridin-2-yl)-2-methyl-piperazin-1-yl]-6-(2-trifluoromethyl-benzyloxy)-[1,3,5]triazin-2-yl]-amine (R);

(4-*tert*-Butyl-phenyl)-{4-chloro-6-[2-methyl-4-(3-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-[1,3,5]triazin-2-yl}-amine (R);

(4-*tert*-Butyl-phenyl)-{4-chloro-6-[4-(3-chloro-pyridin-2-yl)-2-methyl-piperazin-1-yl]-[1,3,5]triazin-2-yl}-amine (R);

(4-*tert*-Butyl-phenyl)-{4-chloro-6-[4-(3-fluoro-pyridin-2-yl)-2-methyl-piperazin-1-yl]-[1,3,5]triazin-2-yl}-amine (R);

(4-*tert*-Butyl-phenyl)-{6-[4-(3-chloro-pyridin-2-yl)-2-methyl-piperazin-1-yl]-pyrimidin-4-yl}-amine (R);

[4-[2-Methyl-4-(3-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-6-(2-trifluoromethyl-benzyloxy)-[1,3,5]triazin-2-yl]-(4-trifluoromethyl-phenyl)-amine (R);

[4-[2-Methyl-4-(3-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-6-(4-trifluoromethyl-phenyl)-[1,3,5]triazin-2-yl]-(4-trifluoromethyl-phenyl)-amine (S);

[4-[4-(3-Chloro-pyridin-2-yl)-2-methyl-piperazin-1-yl]-6-(2,4-dimethoxy-phenyl)-[1,3,5]triazin-2-yl]-(4-trifluoromethyl-phenyl)-amine;

[4-[4-(3-Chloro-pyridin-2-yl)-2-methyl-piperazin-1-yl]-6-(2-trifluoromethyl-benzyloxy)-[1,3,5]triazin-2-yl]-(4-trifluoromethyl-phenyl)-amine (R);

[4-[4-(3-Chloro-pyridin-2-yl)-2-methyl-piperazin-1-yl]-6-(4-isopropyl-phenyl)-[1,3,5]triazin-2-yl]-(4-trifluoromethyl-phenyl)-amine;

[4-[4-(3-Chloro-pyridin-2-yl)-piperazin-1-yl]-6-(2-methyl-pyrrolidin-1-yl)-[1,3,5]triazin-2-yl]-(3-fluoro-phenyl)-amine;

[4-[4-(3-Fluoro-pyridin-2-yl)-2-methyl-piperazin-1-yl]-6-(2-trifluoromethyl-benzyloxy)-[1,3,5]triazin-2-yl]-(4-trifluoromethyl-phenyl)-amine (R);

{2-Diethylaminomethyl-6-[4-(3-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-pyrimidin-4-yl}-(3,4-difluoro-phenyl)-amine;

{4-(2-Chloro-phenyl)-6-[2-methyl-4-(3-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-[1,3,5]triazin-2-yl}-(4-trifluoromethyl-phenyl)-amine (S);

{4-(3,4-Difluoro-phenylamino)-6-[4-(3-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-pyrimidin-2-yl}-methanol;

{4-(4-Butyl-phenyl)-6-[4-(3-chloro-pyridin-2-yl)-2-methyl-piperazin-1-yl]-[1,3,5]triazin-2-yl}-(4-trifluoromethyl-phenyl)-amine;

{4,6-Bis-[4-(3-chloro-pyridin-2-yl)-piperazin-1-yl]-[1,3,5]triazin-2-yl}-(4-trifluoromethyl-phenyl)-amine;

{4-[4-(3-Chloro-pyridin-2-yl)-2-methyl-piperazin-1-yl]-6-morpholin-4-yl-[1,3,5]triazin-2-yl}-(3,4-difluoro-phenyl)-amine (R);

{4-[4-(3-Chloro-pyridin-2-yl)-2-methyl-piperazin-1-yl]-6-morpholin-4-yl-[1,3,5]triazin-2-yl}-(3-fluoro-phenyl)-amine;

{4-[4-(3-Chloro-pyridin-2-yl)-piperazin-1-yl]-6-methyl-[1,3,5]triazin-2-yl}-(4-trifluoromethyl-phenyl)-amine;

{4-[4-(3-Chloro-pyridin-2-yl)-piperazin-1-yl]-6-morpholin-4-yl-[1,3,5]triazin-2-yl}-(3-fluoro-phenyl)-amine;

{4-[4-(3-Chloro-pyridin-2-yl)-piperazin-1-yl]-6-morpholin-4-yl-[1,3,5]triazin-2-yl}-(4-fluoro-phenyl)-amine;

{4-[4-(3-Chloro-pyridin-2-yl)-piperazin-1-yl]-6-morpholin-4-yl-[1,3,5]triazin-2-yl}-p-tolyl-amine;

{4-[4-(3-Chloro-pyridin-2-yl)-piperazin-1-yl]-6-morpholin-4-yl-[1,3,5]triazin-2-yl}-(3,4-difluoro-phenyl)-amine;

{4-[4-(3-Chloro-pyridin-2-yl)-piperazin-1-yl]-6-morpholin-4-yl-[1,3,5]triazin-2-yl}-(4-trifluoromethyl-phenyl)-amine;

{4-[4-(3-Chloro-pyridin-2-yl)-piperazin-1-yl]-6-morpholin-4-yl-[1,3,5]triazin-2-yl}-phenyl-amine;

{4-[4-(3-Chloro-pyridin-2-yl)-piperazin-1-yl]-6-piperidin-1-yl-[1,3,5]triazin-2-yl}-(4-trifluoromethyl-phenyl)-amine;

{4-[4-(3-Chloro-pyridin-2-yl)-piperazin-1-yl]-6-piperidin-1-yl-[1,3,5]triazin-2-yl}-(3-fluoro-phenyl)-amine;

{4-[4-(3-Chloro-pyridin-2-yl)-piperazin-1-yl]-6-pyrrolidin-1-yl-[1,3,5]triazin-2-yl}-(3-fluoro-phenyl)-amine;

{4-Azepan-1-yl-6-[4-(3-chloro-pyridin-2-yl)-piperazin-1-yl]-[1,3,5]triazin-2-yl}-(3-fluoro-phenyl)-amine;

{4-Chloro-6-[2-methyl-4-(3-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-[1,3,5]triazin-2-yl}-(4-trifluoromethyl-phenyl)-amine (S);

{4-Chloro-6-[4-(3-chloro-pyridin-2-yl)-2-methyl-piperazin-1-yl]-[1,3,5]triazin-2-yl}-[4-(1,2,2,2-tetrafluoro-1-trifluoromethyl-ethyl)-phenyl]-amine (R);

{4-Chloro-6-[4-(3-chloro-pyridin-2-yl)-piperazin-1-yl]-[1,3,5]triazin-2-yl}-(4-trifluoromethyl-phenyl)-amine;

{4-Morpholin-4-yl-6-[4-(3-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-[1,3,5]triazin-2-yl}-(4-trifluoromethyl-phenyl)-amine;

{4-Morpholin-4-yl-6-[4-(3-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-[1,3,5]triazin-2-yl}-p-tolyl-amine;

{4-Morpholin-4-yl-6-[4-(3-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-pyrimidin-2-yl}-o-tolyl-amine;

{4-Morpholin-4-yl-6-[4-(3-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-pyrimidin-2-yl}-m-tolyl-amine;

{4-Morpholin-4-yl-6-[4-(3-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-pyrimidin-2-yl}-p-tolyl-amine;

{6-Chloro-2-[4-(3-chloro-pyridin-2-yl)-2-methyl-piperazin-1-yl]-pyrimidin-4-yl}-(4-trifluoromethyl-phenyl)-amine (R);

{6-Morpholin-4-yl-2-[4-(3-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-pyrimidin-4-yl}-p-tolyl-amine;

4-{4-[4-(3-Chloro-pyridin-2-yl)-piperazin-1-yl]-6-diethylamino-[1,3,5]triazin-2-ylamino}-benzonitrile;

6-[4-(3-Chloro-pyridin-2-yl)-2-methyl-piperazin-1-yl]-N-(3,4-difluoro-phenyl)-N',N'-diethyl-[1,3,5]triazine-2,4-diamine (R);

6-[4-(3-Chloro-pyridin-2-yl)-2-methyl-piperazin-1-yl]-N-(3-methyl-butyl)-N'-(4-trifluoromethyl-phenyl)-[1,3,5]triazine-2,4-diamine (R);

6-[4-(3-Chloro-pyridin-2-yl)-2-methyl-piperazin-1-yl]-N-(3-phenyl-propyl)-N'-(4-trifluoromethyl-phenyl)-[1,3,5]triazine-2,4-diamine (R);

6-[4-(3-Chloro-pyridin-2-yl)-2-methyl-piperazin-1-yl]-N-(3-trifluoromethyl-benzyl)-N'-(4-trifluoromethyl-phenyl)-[1,3,5]triazine-2,4-diamine (R);

6-[4-(3-Chloro-pyridin-2-yl)-2-methyl-piperazin-1-yl]-N,N-dimethyl-N'-(4-trifluoromethyl-phenyl)-[1,3,5]triazine-2,4-diamine (R);

6-[4-(3-Chloro-pyridin-2-yl)-2-methyl-piperazin-1-yl]-N,N-dimethyl-N'-(4-trifluoromethyl-phenyl)-[1,3,5]triazine-2,4-diamine (S);

6-[4-(3-Chloro-pyridin-2-yl)-2-methyl-piperazin-1-yl]-N,N-dipropyl-N'-(4-trifluoromethyl-phenyl)-[1,3,5]triazine-2,4-diamine (R);

6-[4-(3-Chloro-pyridin-2-yl)-2-methyl-piperazin-1-yl]-N-isobutyl-N'-[4-(1,2,2,2-tetrafluoro-1-trifluoromethyl-ethyl)-phenyl]-[1,3,5]triazine-2,4-diamine (R);

6-[4-(3-Chloro-pyridin-2-yl)-2-methyl-piperazin-1-yl]-N-isobutyl-N'-(4-trifluoromethyl-phenyl)-[1,3,5]triazine-2,4-diamine (R);

6-[4-(3-Chloro-pyridin-2-yl)-2-methyl-piperazin-1-yl]-N-isopropyl-N-methyl-N'-(4-trifluoromethyl-phenyl)-[1,3,5]triazine-2,4-diamine (R);

6-[4-(3-Chloro-pyridin-2-yl)-2-methyl-piperazin-1-yl]-N-methyl-N-propyl-N'-(4-trifluoromethyl-phenyl)-[1,3,5]triazine-2,4-diamine (R);

6-[4-(3-Chloro-pyridin-2-yl)-2-methyl-piperazin-1-yl]-N-propyl-N'-(4-trifluoromethyl-phenyl)-[1,3,5]triazine-2,4-diamine (R);

6-[4-(3-Chloro-pyridin-2-yl)-2-methyl-piperazin-1-yl]-N-propyl-N'-[4-(1,2,2,2-tetrafluoro-1-trifluoromethyl-ethyl)-phenyl]-[1,3,5]triazine-2,4-diamine (R);

6-[4-(3-Chloro-pyridin-2-yl)-piperazin-1-yl]-N-(3,4-difluoro-phenyl)-N',N'-diethyl-[1,3,5]triazine-2,4-diamine;

6-[4-(3-Chloro-pyridin-2-yl)-piperazin-1-yl]-N-(3-fluoro-phenyl)-N'-methyl-N'-propyl-[1,3,5]triazine-2,4-diamine;

6-[4-(3-Chloro-pyridin-2-yl)-piperazin-1-yl]-N-(3-fluoro-phenyl)-N',N'-dimethyl-[1,3,5]triazine-2,4-diamine;

6-[4-(3-Chloro-pyridin-2-yl)-piperazin-1-yl]-N-(3-fluoro-phenyl)-N'-isopropyl-N'-methyl-[1,3,5]triazine-2,4-diamine;

6-[4-(3-Chloro-pyridin-2-yl)-piperazin-1-yl]-N-(3-fluoro-phenyl)-N'-propyl-[1,3,5]triazine-2,4-diamine;

6-[4-(3-Chloro-pyridin-2-yl)-piperazin-1-yl]-N,N-diethyl-N'-(3-fluoro-phenyl)-[1,3,5]triazine-2,4-diamine;

6-[4-(3-Chloro-pyridin-2-yl)-piperazin-1-yl]-N,N-diethyl-N'-(3-methoxy-phenyl)-[1,3,5]triazine-2,4-diamine;

6-[4-(3-Chloro-pyridin-2-yl)-piperazin-1-yl]-N,N-diethyl-N'-(4-fluoro-phenyl)-[1,3,5]triazine-2,4-diamine;

6-[4-(3-Chloro-pyridin-2-yl)-piperazin-1-yl]-N,N-dimethyl-N'-(4-trifluoromethyl-phenyl)-[1,3,5]triazine-2,4-diamine;

6-[4-(3-Chloro-pyridin-2-yl)-piperazin-1-yl]-N-ethyl-N'-(3-fluoro-phenyl)-N-methyl-[1,3,5]triazine-2,4-diamine;

6-[4-(3-Chloro-pyridin-2-yl)-piperazin-1-yl]-N-ethyl-N'-(3-fluoro-phenyl)-N-isopropyl-[1,3,5]triazine-2,4-diamine;

6-[4-(3-Chloro-pyridin-2-yl)-piperazin-1-yl]-N-ethyl-N-isopropyl-N'-(4-trifluoromethyl-phenyl)-[1,3,5]triazine-2,4-diamine;

6-[4-(3-Chloro-pyridin-2-yl)-piperazin-1-yl]-N-isopropyl-N-methyl-N'-(4-trifluoromethyl-phenyl)-[1,3,5]triazine-2,4-diamine;

6-[4-(3-Chloro-pyridin-2-yl)-piperazin-1-yl]-N-isopropyl-N-methyl-N'-phenyl-[1,3,5]triazine-2,4-diamine;

6-[4-(3-Chloro-pyridin-2-yl)-piperazin-1-yl]-N-methyl-N'-(4-trifluoromethyl-phenyl)-[1,3,5]triazine-2,4-diamine;

N-(2,5-Dimethoxy-phenyl)-N',N'-diethyl-6-(4-pyridin-2-yl-piperazin-1-yl)-[1,3,5]triazine-2,4-diamine;

N-(3,4-Difluoro-phenyl)-N',N'-diethyl-6-(4-pyridin-2-yl-piperazin-1-yl)-[1,3,5]triazine-2,4-diamine;

N-(3,4-Difluoro-phenyl)-N',N'-diethyl-6-[2-methyl-4-(3-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-[1,3,5]triazine-2,4-diamine (R);

N-(3,4-Difluoro-phenyl)-N',N'-diethyl-6-[4-(3-methanesulfonyl-pyridin-2-yl)-2-methyl-piperazin-1-yl]-[1,3,5]triazine-2,4-diamine (R);

N-(3-Chloro-phenyl)-6-[4-(3-chloro-pyridin-2-yl)-piperazin-1-yl]-N',N'-diethyl-[1,3,5]triazine-2,4-diamine;

N-(3-Methyl-butyl)-6-[2-methyl-4-(3-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-N'-(4-trifluoromethyl-phenyl)-[1,3,5]triazine-2,4-diamine (S);

N-(3-Methyl-butyl)-N'-(4-trifluoromethyl-phenyl)-6-[4-(3-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-[1,3,5]triazine-2,4-diamine;

N,N-Diallyl-6-[4-(3-chloro-pyridin-2-yl)-2-methyl-piperazin-1-yl]-N'-(4-trifluoromethyl-phenyl)-[1,3,5]triazine-2,4-diamine (R);

N,N-Dibutyl-6-[4-(3-chloro-pyridin-2-yl)-2-methyl-piperazin-1-yl]-N'-(4-trifluoromethyl-phenyl)-[1,3,5]triazine-2,4-diamine (R);

N,N-Diethyl-N'-(4-fluoro-phenyl)-6-(4-pyridin-2-yl-piperazin-1-yl)-[1,3,5]triazine-2,4-diamine;

N,N-Dimethyl-6-(4-phenyl-piperazin-1-yl)-N'-(4-trifluoromethyl-phenyl)-[1,3,5]triazine-2,4-diamine;

N,N-Dimethyl-6-(4-pyridin-2-yl-piperazin-1-yl)-N'-(4-trifluoromethyl-phenyl)-[1,3,5]triazine-2,4-diamine;

N,N-Dimethyl-N'-(4-trifluoromethyl-phenyl)-6-[4-(3-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-[1,3,5]triazine-2,4-diamine;

N,N-Dimethyl-N'-phenyl-6-[4-(3-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-[1,3,5]triazine-2,4-diamine;

N-Benzyl-6-[4-(3-chloro-pyridin-2-yl)-2-methyl-piperazin-1-yl]-N'-(4-trifluoromethyl-phenyl)-[1,3,5]triazine-2,4-diamine (R);

N-Butyl-6-[4-(2-chloro-phenyl)-2-methyl-piperazin-1-yl]-N'-[4-(1,2,2,2-tetrafluoro-1-trifluoromethyl-ethyl)-phenyl]-[1,3,5]triazine-2,4-diamine (R);

N-Butyl-6-[4-(2-chloro-phenyl)-2-methyl-piperazin-1-yl]-N'-[4-(1,2,2,2-tetrafluoro-1-trifluoromethyl-ethyl)-phenyl]-[1,3,5]triazine-2,4-diamine (R);

N-Butyl-6-[4-(3-chloro-pyridin-2-yl)-2-methyl-piperazin-1-yl]-N'-(4-trifluoromethyl-phenyl)-[1,3,5]triazine-2,4-diamine (R);

N-Butyl-6-[4-(3-chloro-pyridin-2-yl)-2-methyl-piperazin-1-yl]-N'-(4-trifluoromethyl-phenyl)-[1,3,5]triazine-2,4-diamine (R);

N-Butyl-6-[4-(3-chloro-pyridin-2-yl)-2-methyl-piperazin-1-yl]-N-methyl-N'-(4-trifluoromethyl-phenyl)-[1,3,5]triazine-2,4-diamine (R);

N-Butyl-6-[4-(3-chloro-pyridin-2-yl)-piperazin-1-yl]-N'-(3-fluoro-phenyl)-N-methyl-[1,3,5]triazine-2,4-diamine;

N-Isopropyl-N-methyl-N'-(4-trifluoromethyl-phenyl)-6-[4-(3-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-[1,3,5]triazine-2,4-diamine;

N-Isopropyl-N-methyl-N'-phenyl-6-[4-(3-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-[1,3,5]triazine-2,4-diamine;

N-Methyl-N-propyl-N'-(4-trifluoromethyl-phenyl)-6-[4-(3-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-[1,3,5]triazine-2,4-diamine;

N-sec-Butyl-6-[4-(3-chloro-pyridin-2-yl)-2-methyl-piperazin-1-yl]-N'-[4-(1,2,2,2-tetrafluoro-1-trifluoromethyl-ethyl)-phenyl]-[1,3,5]triazine-2,4-diamine (R); and

Phenyl-{6-piperidin-1-yl-2-[4-(3-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-pyrimidin-4-yl}-amine.

113-228. (Cancelled).

229. (New) A pharmaceutical composition, comprising at least one compound or pharmaceutically acceptable salt thereof according to claim 18 in combination with a physiologically acceptable carrier or excipient.

230. (New) A pharmaceutical composition according to claim 229 wherein the composition is formulated as an injectible fluid, an aerosol, a cream, a gel, a pill, a capsule, a syrup or a transdermal patch.

231. (New) A pharmaceutical composition, comprising at least one compound or pharmaceutically acceptable salt thereof according to claim 38 in combination with a physiologically acceptable carrier or excipient.

232. (New) A pharmaceutical composition according to claim 231 wherein the composition is formulated as an injectible fluid, an aerosol, a cream, a gel, a pill, a capsule, a syrup or a transdermal patch.